Literature DB >> 15169887

Epstein-Barr virus latent membrane protein 1 induces synthesis of hypoxia-inducible factor 1 alpha.

Naohiro Wakisaka1, Satoru Kondo, Tomokazu Yoshizaki, Shigeyuki Murono, Mitsuru Furukawa, Joseph S Pagano.   

Abstract

Hypoxia-inducible factor 1 (HIF-1) is a heterodimeric basic helix-loop-helix transcription factor composed of HIF-1 alpha and HIF-1 beta that is the central regulator of responses to hypoxia. The specific binding of HIF-1 to the hypoxia-responsive element (HRE) induces the transcription of genes that respond to hypoxic conditions, including vascular endothelial growth factor (VEGF). Here we report that expression of HIF-1 alpha is increased in diverse Epstein-Barr virus (EBV)-infected type II and III cell lines, which express EBV latent membrane protein 1 (LMP1), the principal EBV oncoprotein, as well as other latency proteins, but not in the parental EBV-negative cell lines. We show first that transfection of an LMP1 expression plasmid into Ad-AH cells, an EBV-negative nasopharyngeal epithelial cell line, induces synthesis of HIF-1 alpha protein without increasing its stability or mRNA level. The mitogen-activated protein kinase (MAPK) kinase inhibitor PD98059 markedly reduces induction of HIF-1 alpha by LMP1. Catalase, an H(2)O(2) scavenger, strongly suppresses LMP1-induced production of H(2)O(2), which results in a decrease in the expression of HIF-1 alpha induced by LMP1. Inhibition of the NF-kappa B, c-jun N-terminal kinase, p38 MAPK, and phosphatidylinositol 3-kinase pathways did not affect HIF-1 alpha expression. Moreover, LMP1 induces HIF-1 DNA binding activity and upregulates HRE and VEGF promoter transcriptional activity. Finally, LMP1 increases the appearance of VEGF protein in extracellular fluids; induction of VEGF is suppressed by PD98059 or catalase. These results suggest that LMP1 increases HIF-1 activity through induction of HIF-1 alpha protein expression, which is controlled by p42/p44 MAPK activity and H(2)O(2). The ability of EBV, and specifically its major oncoprotein, LMP1, to induce HIF-1 alpha along with other invasiveness and angiogenic factors reported previously discloses additional oncogenic properties of this tumor virus.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15169887      PMCID: PMC419879          DOI: 10.1128/MCB.24.12.5223-5234.2004

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  72 in total

1.  Microtubule disruption utilizes an NFkappa B-dependent pathway to stabilize HIF-1alpha protein.

Authors:  Yun-Jin Jung; Jennifer S Isaacs; Sunmin Lee; Jane Trepel; Len Neckers
Journal:  J Biol Chem       Date:  2002-12-17       Impact factor: 5.157

2.  NF-kappaB plays a key role in hypoxia-inducible factor-1-regulated erythropoietin gene expression.

Authors:  Yanira G Figueroa; Anna K Chan; Rania Ibrahim; Yan Tang; Matthew E Burow; Jawed Alam; Aline B Scandurro; Barbara S Beckman
Journal:  Exp Hematol       Date:  2002-12       Impact factor: 3.084

3.  Prostaglandin E2 induces hypoxia-inducible factor-1alpha stabilization and nuclear localization in a human prostate cancer cell line.

Authors:  Xin Hua Liu; Alexander Kirschenbaum; Min Lu; Shen Yao; Amy Dosoretz; James F Holland; Alice C Levine
Journal:  J Biol Chem       Date:  2002-10-24       Impact factor: 5.157

4.  Hypoxia-inducible factor 1 levels vary exponentially over a physiologically relevant range of O2 tension.

Authors:  B H Jiang; G L Semenza; C Bauer; H H Marti
Journal:  Am J Physiol       Date:  1996-10

5.  A cytoplasmic inhibitor of the JNK signal transduction pathway.

Authors:  M Dickens; J S Rogers; J Cavanagh; A Raitano; Z Xia; J R Halpern; M E Greenberg; C L Sawyers; R J Davis
Journal:  Science       Date:  1997-08-01       Impact factor: 47.728

6.  The Epstein-Barr virus oncogene product latent membrane protein 1 engages the tumor necrosis factor receptor-associated death domain protein to mediate B lymphocyte growth transformation and activate NF-kappaB.

Authors:  K M Izumi; E D Kieff
Journal:  Proc Natl Acad Sci U S A       Date:  1997-11-11       Impact factor: 11.205

7.  Regulation of colon carcinoma cell invasion by hypoxia-inducible factor 1.

Authors:  Balaji Krishnamachary; Shannon Berg-Dixon; Brian Kelly; Faton Agani; David Feldser; Gloria Ferreira; Narayan Iyer; Jessica LaRusch; Brian Pak; Panthea Taghavi; Gregg L Semenza
Journal:  Cancer Res       Date:  2003-03-01       Impact factor: 12.701

Review 8.  Oxidants as stimulators of signal transduction.

Authors:  Y J Suzuki; H J Forman; A Sevanian
Journal:  Free Radic Biol Med       Date:  1997       Impact factor: 7.376

9.  Vascular endothelial growth factor gene expression in colon cancer cells exposed to prostaglandin E2 is mediated by hypoxia-inducible factor 1.

Authors:  Ryo Fukuda; Brian Kelly; Gregg L Semenza
Journal:  Cancer Res       Date:  2003-05-01       Impact factor: 12.701

10.  IL-1beta-mediated up-regulation of HIF-1alpha via an NFkappaB/COX-2 pathway identifies HIF-1 as a critical link between inflammation and oncogenesis.

Authors:  Yun-Jin Jung; Jennifer S Isaacs; Sunmin Lee; Jane Trepel; Len Neckers
Journal:  FASEB J       Date:  2003-09-04       Impact factor: 5.191

View more
  73 in total

Review 1.  Reprogramming of cellular metabolic pathways by human oncogenic viruses.

Authors:  John G Purdy; Micah A Luftig
Journal:  Curr Opin Virol       Date:  2019-11-22       Impact factor: 7.090

2.  Interferon regulatory factor 5 represses expression of the Epstein-Barr virus oncoprotein LMP1: braking of the IRF7/LMP1 regulatory circuit.

Authors:  Shunbin Ning; Leslie E Huye; Joseph S Pagano
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

3.  Kaposi's sarcoma-associated herpesvirus latent protein LANA interacts with HIF-1 alpha to upregulate RTA expression during hypoxia: Latency control under low oxygen conditions.

Authors:  Qiliang Cai; Ke Lan; Subhash C Verma; Huaxin Si; Doug Lin; Erle S Robertson
Journal:  J Virol       Date:  2006-08       Impact factor: 5.103

4.  Epstein-Barr virus latent membrane protein 1 (LMP1) C-terminal-activating region 3 contributes to LMP1-mediated cellular migration via its interaction with Ubc9.

Authors:  Gretchen L Bentz; Christopher B Whitehurst; Joseph S Pagano
Journal:  J Virol       Date:  2011-07-27       Impact factor: 5.103

Review 5.  Strong cross-talk between angiogenesis and EBV: do we need different treatment approaches in lymphoma cases with EBV and/or high angiogenic capacity.

Authors:  Semra Paydas
Journal:  Med Oncol       Date:  2011-09-23       Impact factor: 3.064

6.  Epstein-Barr virus latent membrane protein 1 is not associated with vessel density nor with hypoxia inducible factor 1 alpha expression in nasopharyngeal carcinoma tissue.

Authors:  Alexander A Benders; Weihua Tang; Jaap M Middeldorp; Astrid E Greijer; Leigh B Thorne; William K Funkhouser; W Kimryn Rathmell; Margaret L Gulley
Journal:  Head Neck Pathol       Date:  2009-11-12

7.  Hypoxia-targeting by tirapazamine (TPZ) induces preferential growth inhibition of nasopharyngeal carcinoma cells with Chk1/2 activation.

Authors:  Bo Hong; Vivian W Y Lui; Edwin P Hui; Margaret H L Ng; Suk-Hang Cheng; Fion L Sung; Chi-Man Tsang; Sai-Wah Tsao; Anthony Tak-Cheung Chan
Journal:  Invest New Drugs       Date:  2009-12-16       Impact factor: 3.850

Review 8.  Interdependence of hypoxic and innate immune responses.

Authors:  Victor Nizet; Randall S Johnson
Journal:  Nat Rev Immunol       Date:  2009-09       Impact factor: 53.106

9.  HIF-1α influences myeloid cell antigen presentation and response to subcutaneous OVA vaccination.

Authors:  Tamara Bhandari; Joshua Olson; Randall S Johnson; Victor Nizet
Journal:  J Mol Med (Berl)       Date:  2013-05-19       Impact factor: 4.599

10.  Molecular events associated with epithelial to mesenchymal transition of nasopharyngeal carcinoma cells in the absence of Epstein-Barr virus genome.

Authors:  Jung-Chung Lin; Shuen-Kuei Liao; En-Huei Lee; Man-Shan Hung; Yiyang Sayion; Hung-Chang Chen; Chen-Chen Kang; Liang-Sheng Huang; Jaw-Ming Cherng
Journal:  J Biomed Sci       Date:  2009-11-24       Impact factor: 8.410

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.